SCHOTT Pharma polymer cartridge platform compatible with large-volume SHL Medical autoinjectors

Pre-validated system

SCHOTT Pharma and SHL Medical conducted compatibility studies that assessed both dimensional as well as functional fit of the SCHOTT TOPPAC® polymer cartridge with Maggie® autoinjector platforms. The joint assessment confirmed the full system compatibility. This includes the 3 ml SCHOTT TOPPAC® cartridge with Maggie® 3.0 ml and the 5 ml SCHOTT TOPPAC® cartridge with Maggie® 5.0 ml autoinjector.

This milestone enables access to a pre-validated and de-risked solution for the safe and convenient administration of large-volume medications at home, supporting self‑injection for a wide range of therapies.

As part of the SCHOTT iQ® platform, the polymer cartridge is delivered in an industry-standard nest-and-tub configuration, streamlining fill-and-finish processes and helping to accelerate time to market for pharmaceutical companies.

In addition to the polymer option, SCHOTT Pharma’s 3 ml and 5 ml cartriQ® glass cartridges are also compatible with the Maggie® 3.0 ml and 5.0 ml autoinjectors, providing pharmaceutical companies with options for material choice tailored to the specific needs of each therapy and patient population.

Expanding compatibility with further medical devices

Building on this achievement, SCHOTT Pharma and SHL Medical are expanding their collaboration with future studies assessing the compatibility of the SCHOTT TOPPAC® polymer cartridge with SHL Medical’s pen systems. SCHOTT Pharma is also exploring opportunities to extend compatibility to additional medical devices in the future.

“Our strong partnership with SCHOTT Pharma has been instrumental in driving both productivity and innovation. By working hand in hand, we’re developing solutions that meet the evolving needs of patients and industry stakeholders,” emphasizes Markus Puusepp, Chief Growth Officer at SHL Medical. “We are excited to continue this close collaboration, leveraging the SCHOTT TOPPAC® cartridge alongside our advanced injection device systems to deliver even greater value.”

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Further information at www.schott-pharma.com